Heart-related diseases have
become extremely common due to the hectic lifestyle led by people. Some people
are diagnosed with arrhythmia, an irregular heartbeat that can prove fatal.
More than 2 million people in the U.S. reportedly suffer from Atrial
Fibrillation (AF), a type of arrhythmia, and the geriatric populace is highly
susceptible to the same.
Cardiac Resynchronization
Therapy (CRT) is a device designed to treat heart failure. It sends electrical
impulses to the lower chambers of heart, which facilitates synchronized heart
beats. CRT-P (CRT-pacemaker) and CRT-D (CRT-defibrillator) are two types of
implantable cardioverter defibrillators (ICDs) that aid in treating heart
failure. A CRT-D device can treat arrhythmia by delivering shock to the heart,
while a CRT-P device does the same when it beats at an abnormally slow rate.
Novel Developments
EBR Systems, Inc., an
American manufacturer of cardiac implants, has received U.S. FDA approval for
the “Wireless Stimulation Endocardially” (WiSE) technology to reduce the
dependency on lead pacemakers to treat heart failure. It boasts of being the
world’s only wireless pacemaker that stimulates the endocardium of the left
ventricle. It has been reported that a significant percentage of consumers
responded positively to this therapy. WiSE is expected to benefit nearly 1.5
million patients globally.
In 2016, Medtronic Plc
received approval from U.S. FDA for its proprietary product “Claria MRI Quad
Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan.” Medtronic’s
EffectivCRT Diagnostic, which automatically estimates the strength of each left
ventricular pace, is a component of Claria. Claria automatically adjusts pacing
rates during AF, without adversely impacting the average heart rate. This
device is designed to run in 1.5 and 3 Tesla Magnetic Resonance Imaging (MRI)
machines.
Market Outlook
The global cardiac
resynchronization therapy (CRT) market is anticipated to
reach USD 8 billion by 2025. The rising cases of heart failure worldwide are
expected to spur market demand from 2014 to 2025 (forecast period).
The Sudden Cardiac Arrest
Foundation has estimated that nearly 6 million suffer from cardiac disorders.
This is anticipated to spur market growth in order to minimize hospital costs.
CRT-D devices are anticipated to dominate the market over the forecast period.
North America accounted for
over 30% of the market share in 2015 due to the growing regional geriatric
population. Latin America and Asia Pacific are expected to contribute over 30%
to global revenue by 2025. Some of the prominent market players are Boston
Scientific Corporation, LivaNova Plc., and Medtronic Plc.
In-Depth research report on cardiac resynchronization
therapy (CRT) market:
No comments:
Post a Comment